

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims.

1.-34. (Canceled)

35. (Previously Presented): An isolated antibody or portion thereof that specifically binds to a protein selected from the group consisting of:

(a) a protein whose sequence consists of amino acid residues -21 to 69 of SEQ ID NO: 4;

(b) a protein whose sequence consists of amino acid residues 1 to 69 of SEQ ID NO: 4;

(c) a protein whose sequence consists of an antigenic fragment of the amino acid sequence of SEQ ID NO: 4;

(d) a protein consisting of a fragment of SEQ ID NO: 4, wherein said fragment comprises at least 30 contiguous amino acid residues of SEQ ID NO: 4; and

(e) a protein consisting of a fragment of SEQ ID NO: 4, wherein said fragment comprises at least 50 contiguous amino acid residues of SEQ ID NO: 4.

36. (Previously Presented): The antibody or portion thereof of claim 35 that specifically binds protein (a).

37. (Previously Presented): The antibody or portion thereof of claim 35 that specifically binds protein (b).

38. (Previously Presented): The antibody or portion thereof of claim 35 that specifically binds protein (c).

39. (Previously Presented): The antibody or portion thereof of claim 35 that specifically binds protein (d).

40. (Previously Presented): The antibody or portion thereof of claim 35 that specifically binds protein (e).

41. (Previously Presented): The antibody or portion thereof of claim 35 wherein said protein specifically bound by said antibody or portion thereof is glycosylated.

42. (Previously Presented): The antibody or portion thereof of claim 35 which is a monoclonal antibody.

43. (Previously Presented): The antibody or portion thereof of claim 35 which is a polyclonal antibody.

44. (Previously Presented): The antibody or portion thereof of claim 35 which is a chimeric antibody.

45. (Previously Presented): The antibody or portion thereof of claim 35 which is a humanized antibody.

46. (Previously Presented): The antibody or portion thereof of claim 35 which is a human antibody.

47. (Previously Presented): The antibody or portion thereof of claim 35 which is a single chain antibody.

48. (Previously Presented): The antibody or portion thereof of claim 35 which is a Fab fragment.

49. (Previously Presented): A composition comprising the antibody or portion thereof of claim 35 and a carrier.

50. (Previously Presented): The composition of claim 49, wherein the antibody or portion thereof is a monoclonal antibody.

51. (Previously Presented): The composition of claim 49, wherein the antibody or portion thereof is a chimeric antibody.

52. (Previously Presented): The composition of claim 49, wherein the antibody or portion thereof is a humanized antibody.

53. (Previously Presented): The composition of claim 49, wherein the antibody or portion thereof is a human antibody.

54. (Previously Presented): The composition of claim 49, wherein the antibody or portion thereof is a single chain antibody.

55. (Previously Presented): The composition of claim 49, wherein the antibody or portion thereof is a Fab fragment.

56. (Previously Presented): An isolated cell that produces the antibody of claim 35.

57. (Previously Presented): A hybridoma that produces the antibody of claim 35.

58. (Previously Presented): A hybridoma that produces the antibody of claim 42.

59. (Previously Presented): A method of detecting hESF II protein in a biological sample comprising:

(a) contacting the biological sample with the antibody or portion thereof of claim 35; and

(b) detecting the hESF II protein in the biological sample by its binding to the antibody or portion thereof.

60. (Previously Presented): The method of claim 59 wherein the antibody is a monoclonal antibody.

61. (Previously Presented): The method of claim 59 wherein the antibody is a polyclonal antibody.

62. (Previously Presented): The method of claim 59 wherein the antibody is a chimeric antibody.

63. (Previously Presented): The method of claim 59 wherein the antibody is a humanized antibody.

64. (Previously Presented): The method of claim 59 wherein the antibody is a human antibody.

65. (Previously Presented): The method of claim 59 wherein the antibody is a single chain antibody.

66. (Previously Presented): An isolated antibody or portion thereof produced by immunizing an animal with a protein selected from the group consisting of:

(a) a protein whose sequence comprises amino acid residues -21 to 69 of SEQ ID NO: 4;

(b) a protein whose sequence comprises amino acid residues 1 to 69 of SEQ ID NO: 4;

(c) a protein whose sequence comprises an antigenic fragment of the amino acid sequence of SEQ ID NO: 4;

(d) a protein whose sequence comprises at least 30 contiguous amino acid residues of SEQ ID NO: 4; and

(e) a protein whose sequence comprises at least 50 contiguous amino acid residues of SEQ ID NO: 4,

wherein said antibody or portion thereof specifically binds to the amino acid sequence of SEQ ID NO: 4.

67. (Previously Presented): The antibody or portion thereof of claim 66 produced by immunizing an animal with protein (a).

68. (Previously Presented): The antibody or portion thereof of claim 66 produced by immunizing an animal with protein (b).

69. (Previously Presented): The antibody or portion thereof of claim 66 produced by immunizing an animal with protein (c).

70. (Previously Presented): The antibody or portion thereof of claim 66 produced by immunizing an animal with protein (d).

71. (Previously Presented): The antibody or portion thereof of claim 66 produced by immunizing an animal with protein (e).

72. (Canceled)

73. (Currently Amended): The antibody or portion thereof of claim ~~37~~ 66 wherein said protein specifically bound by said antibody or portion thereof is glycosylated.

74. (Currently Amended): The antibody or portion thereof of claim ~~37~~ 66 which is a monoclonal antibody.

75. (Currently Amended): The antibody or portion thereof of claim ~~37~~ 66 which is a polyclonal antibody.

76. (Currently Amended): The antibody or portion thereof of claim ~~37~~ 66 which is a chimeric antibody.

77. (Currently Amended): The antibody or portion thereof of claim ~~37~~ 66 which is a humanized antibody.

78. (Currently Amended): The antibody or portion thereof of claim ~~37~~ 66 which is a human antibody.

79. (Currently Amended): The antibody or portion thereof of claim ~~37~~ 66 which is a single chain antibody.

80. (Currently Amended): The antibody or portion thereof of claim ~~37~~ 66 which is a Fab fragment.

81. (Currently Amended): A composition comprising the antibody or portion thereof of claim ~~37~~ 66 and a carrier.

82. (Previously Presented): The composition of claim 81, wherein the antibody or portion thereof is a monoclonal antibody.

83. (Previously Presented): The composition of claim 81, wherein the antibody or portion thereof is a chimeric antibody.

84. (Previously Presented): The composition of claim 81, wherein the antibody or portion thereof is a humanized antibody.

85. (Previously Presented): The composition of claim 81, wherein the antibody or portion thereof is a human antibody.

86. (Previously Presented): The composition of claim 81, wherein the antibody or portion thereof is a single chain antibody.

87. (Previously Presented): The composition of claim 81, wherein the antibody or portion thereof is a Fab fragment.

88. (Currently Amended): An isolated cell that produces the antibody of claim 37
66.

89. (Currently Amended): A hybridoma that produces the antibody of claim 3766.

90. (Previously Presented): A hybridoma that produces the antibody of claim 74.

91. (Currently Amended): A method of detecting hESF II protein in a biological sample comprising:

(a) contacting the biological sample with the antibody or portion thereof of claim 3766; and

(b) detecting the hESF II protein in the biological sample by its binding to the antibody or portion thereof.

92. (Previously Presented): The method of claim 91 wherein the antibody is a monoclonal antibody.

93. (Previously Presented): The method of claim 91 wherein the antibody is a polyclonal antibody.

94. (Previously Presented): The method of claim 91 wherein the antibody is a chimeric antibody.

95. (Previously Presented): The method of claim 91 wherein the antibody is a humanized antibody.

96. (Previously Presented): The method of claim 91 wherein the antibody is a human antibody.

97. (Previously Presented): The method of claim 91 wherein the antibody is a single chain antibody.

98. (Previously Presented): The method of claim 91 wherein the antibody or portion thereof is a Fab fragment.

99. (Previously Presented): An isolated antibody or portion thereof that specifically binds to a protein selected from the group consisting of:

(a) a protein whose sequence consists of the amino acid sequence of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit Number 97402;

(b) a protein whose sequence consists of the amino acid sequence of the mature polypeptide encoded by the cDNA contained in ATCC Deposit Number 97402;

(c) a protein whose sequence consists of an antigenic fragment of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 97402;

(d) a protein consisting of a fragment of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 97402, wherein said fragment comprises at least 30 contiguous amino acid residues of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 97402; and

(e) a protein consisting of a fragment of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 97402, wherein said fragment comprises at least 50 contiguous amino acid residues of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 97402.

100. (Previously Presented): The antibody or portion thereof of claim 99 that specifically binds protein (a).

101. (Previously Presented): The antibody or portion thereof of claim 99 that specifically binds protein (b).

102. (Previously Presented): The antibody or portion thereof of claim 99 that specifically binds protein (c).

103. (Previously Presented): The antibody or portion thereof of claim 99 that specifically binds protein (d).

104. (Previously Presented): The antibody or portion thereof of claim 99 that specifically binds protein (e).

105. (Previously Presented): The antibody or portion thereof of claim 99 wherein said protein specifically bound by said antibody or portion thereof is glycosylated.

106. (Previously Presented): The antibody or portion thereof of claim 99 which is a monoclonal antibody.

107. (Previously Presented): The antibody or portion thereof of claim 99 which is a polyclonal antibody.

108. (Previously Presented): The antibody or portion thereof of claim 99 which is a chimeric antibody.

109. (Previously Presented): The antibody or portion thereof of claim 99 which is a humanized antibody.

110. (Previously Presented): The antibody or portion thereof of claim 99 which is a human antibody.

111. (Previously Presented): The antibody or portion thereof of claim 99 which is a single chain antibody.

112. (Previously Presented): The antibody or portion thereof of claim 99 which is a Fab fragment.

113. (Previously Presented): A composition comprising the antibody or portion thereof of claim 99 and a carrier.

114. (Previously Presented): The composition of claim 113, wherein the antibody or portion thereof is a monoclonal antibody.

115. (Previously Presented): The composition of claim 113, wherein the antibody or portion thereof is a chimeric antibody.

116. (Previously Presented): The composition of claim 113, wherein the antibody or portion thereof is a humanized antibody.

117. (Previously Presented): The composition of claim 113, wherein the antibody or portion thereof is a human antibody.

118. (Previously Presented): The composition of claim 113, wherein the antibody or portion thereof is a single chain antibody.

119. (Previously Presented): The composition of claim 113, wherein the antibody or portion thereof is a Fab fragment.

120. (Previously Presented): An isolated cell that produces the antibody of claim 99.

121. (Previously Presented): A hybridoma that produces the antibody of claim 99.

122. (Previously Presented): A hybridoma that produces the antibody of claim 106.

123. (Previously Presented): A method of detecting hESF II protein in a biological sample comprising:

(a) contacting the biological sample with the antibody or portion thereof of claim 99; and

(b) detecting the hESF II protein in the biological sample by its binding to the antibody or portion thereof.

124. (Previously Presented): The method of claim 123 wherein the antibody is a monoclonal antibody.

125. (Previously Presented): The method of claim 123 wherein the antibody is a polyclonal antibody.

126. (Previously Presented): The method of claim 123 wherein the antibody is a chimeric antibody.

127. (Previously Presented): The method of claim 123 wherein the antibody is a humanized antibody.

128. (Previously Presented): The method of claim 123 wherein the antibody is a human antibody.

129. (Previously Presented): The method of claim 123 wherein the antibody is a single chain antibody.

130. (Previously Presented): An isolated antibody or portion thereof produced by immunizing an animal with a protein selected from the group consisting of:

(a) a protein whose sequence comprises the amino acid sequence of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit Number 97402;

(b) a protein whose sequence comprises the amino acid sequence of the mature polypeptide encoded by the cDNA contained in ATCC Deposit Number 97402;

(c) a protein whose sequence comprises an antigenic fragment of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 97402;

(d) a protein whose sequence comprises at least 30 contiguous amino acid residues of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 97402; and,
(e) a protein whose sequence comprises at least 50 contiguous amino acid residues of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 97402;
wherein said antibody or portion thereof specifically binds to the polypeptide encoded by the cDNA contained in ATCC Deposit Number 97402.

131. (Previously Presented): The antibody or portion thereof of claim 130 produced by immunizing an animal with protein (a).

132. (Previously Presented): The antibody or portion thereof of claim 130 produced by immunizing an animal with protein (b).

133. (Previously Presented): The antibody or portion thereof of claim 130 produced by immunizing an animal with protein (c).

134. (Previously Presented): The antibody or portion thereof of claim 130 produced by immunizing an animal with protein (d).

135. (Previously Presented): The antibody or portion thereof of claim 130 produced by immunizing an animal with protein (e).

136. (Canceled)

137. (Currently Amended): The antibody or portion thereof of claim ~~101~~ 130 wherein said protein specifically bound by said antibody or portion thereof is glycosylated.

138. (Currently Amended): The antibody or portion thereof of claim ~~101~~ 130 which is a monoclonal antibody.

139. (Currently Amended): The antibody or portion thereof of claim ~~101~~ 130 which is a polyclonal antibody.

140. (Currently Amended): The antibody or portion thereof of claim ~~101~~ 130 which is a chimeric antibody.

141. (Currently Amended): The antibody or portion thereof of claim ~~101~~ 130 which is a humanized antibody.

142. (Currently Amended): The antibody or portion thereof of claim ~~101~~ 130 which is a human antibody.

143. (Currently Amended): The antibody or portion thereof of claim ~~101~~ 130 which is a single chain antibody.

144. (Currently Amended): The antibody or portion thereof of claim ~~101~~ 130 which is a Fab fragment.

145. (Currently Amended): A composition comprising the antibody or portion thereof of claim ~~101~~ 130 and a carrier.

146. (Previously Presented): The composition of claim 145, wherein the antibody or portion thereof is a monoclonal antibody.

147. (Previously Presented): The composition of claim 145, wherein the antibody or portion thereof is a chimeric antibody.

148. (Previously Presented): The composition of claim 145, wherein the antibody or portion thereof is a humanized antibody.

149. (Previously Presented): The composition of claim 145, wherein the antibody or portion thereof is a human antibody.

150. (Previously Presented): The composition of claim 145, wherein the antibody or portion thereof is a single chain antibody.

151. (Previously Presented): The composition of claim 145, wherein the antibody or portion thereof is a Fab fragment.

152. (Currently Amended): An isolated cell that produces the antibody of claim ~~101~~ 130.

153. (Currently Amended): A hybridoma that produces the antibody of claim ~~101~~ 130.

154. (Previously Presented): A hybridoma that produces the antibody of claim 138.

155. (Currently Amended): A method of detecting hESF II protein in a biological sample comprising:

(a) contacting the biological sample with the antibody or portion thereof of claim ~~101~~ 130; and

(b) detecting the hESF II protein in the biological sample by its binding to the antibody or portion thereof.

156. (Previously Presented): The method of claim 155 wherein the antibody is a monoclonal antibody.

157. (Previously Presented): The method of claim 155 wherein the antibody is a polyclonal antibody.

158. (Previously Presented): The method of claim 155 wherein the antibody is a chimeric antibody.

159. (Previously Presented): The method of claim 155 wherein the antibody is a humanized antibody.

160. (Previously Presented): The method of claim 155 wherein the antibody is a human antibody.

161. (Previously Presented): The method of claim 155 wherein the antibody is a single chain antibody.

162. (New): The method of claim 155 wherein the antibody or portion thereof is a Fab fragment.